Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 984041, 6 pages
http://dx.doi.org/10.1155/2013/984041
Research Article

Disease Modifying Therapies for Alzheimer's Disease Targeting Aβ Oligomers: Implications for Therapeutic Mechanisms

1Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Aomori 036-8562, Japan
2Shin-Yurigaoka General Hospital, Kanagawa 215-0026, Japan
3Immunas Pharma Incorporation, Kanagawa 213-0012, Japan

Received 30 April 2013; Revised 22 July 2013; Accepted 22 July 2013

Academic Editor: Patrick Kehoe

Copyright © 2013 Etsuro Matsubara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Hardy and G. A. Higgins, “Alzheimer's disease: the amyloid cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185, 1992. View at Google Scholar · View at Scopus
  2. D. Schenk, R. Barbour, W. Dunn et al., “Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. L. A. Kotilinek, B. Bacskai, M. Westerman et al., “Reversible memory loss in a mouse transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 22, no. 15, pp. 6331–6335, 2002. View at Google Scholar · View at Scopus
  4. F. Bard, C. Cannon, R. Barbour et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nature Medicine, vol. 6, no. 8, pp. 916–919, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Bard, R. Barbour, C. Cannon et al., “Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 4, pp. 2023–2028, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Selkoe, “Alzheimer's disease is a synaptic failure,” Science, vol. 298, no. 5594, pp. 789–791, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Haass and D. J. Selkoe, “Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide,” Nature Reviews Molecular Cell Biology, vol. 8, no. 2, pp. 101–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. P. Lambert, A. K. Barlow, B. A. Chromy et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6448–6453, 1998. View at Google Scholar · View at Scopus
  9. R. Kayed, E. Head, J. L. Thompson et al., “Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis,” Science, vol. 300, no. 5618, pp. 486–489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Akiyama, S. Barger, S. Bamum et al., “Inflammation and Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000. View at Google Scholar
  11. Y. Gong, L. Chang, K. L. Viola et al., “Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10417–10422, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Hoshi, M. Sato, S. Matsumoto et al., “Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6370–6375, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. P. N. Lacor, M. C. Buniel, L. Chang et al., “Synaptic targeting by Alzheimer's-related amyloid β oligomers,” Journal of Neuroscience, vol. 24, no. 45, pp. 10191–10200, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. Cleary, D. M. Walsh, J. J. Hofmeister et al., “Natural oligomers of the amyloid-β protein specifically disrupt cognitive function,” Nature Neuroscience, vol. 8, no. 1, pp. 79–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. P. N. Lacor, M. C. Buniel, P. W. Furlow et al., “Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease,” Journal of Neuroscience, vol. 27, no. 4, pp. 796–807, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Takamura, Y. Okamoto, T. Kawarabayashi et al., “Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse,” Molecular Neurodegeneration, vol. 6, no. 1, article 20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Takamura, Y. Sato, D. Watabe et al., “Sortilin is required for toxic action of Aβ oligomers (AβOs): extracellular AβOs triggers apoptosis, and intracellular AβOs impair degradation pathways,” Life Sciences, vol. 10, no. 23-24, pp. 1177–1186, 2012. View at Google Scholar
  18. J. A. R. Nicolll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, “Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report,” Nature Medicine, vol. 9, no. 4, pp. 448–452, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. R. B. DeMattos, K. R. Bales, D. J. Cummins, J.-C. Dodart, S. M. Paul, and D. M. Holtzman, “Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8850–8855, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Deane, A. Sagare, K. Hamm et al., “IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor,” Journal of Neuroscience, vol. 25, no. 50, pp. 11495–11503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon, “Disaggregation of Alzheimer β-amyloid by site-directed mAb,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 8, pp. 4109–4112, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Yamada, C. Yabuki, P. Seubert et al., “Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ,” Journal of Neuroscience, vol. 29, no. 36, pp. 11393–11398, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Matsubara and A. Takamura, “Molecular mechanism underlying Aβ immunotherapy: implications for the toxic action of Aβ oligomers,” Journal of Gerontology & Geriatric Research, vol. S2, p. 001, 2012. View at Publisher · View at Google Scholar
  24. N. Yamamoto, E. Matsubara, S. Maeda et al., “A ganglioside-induced toxic soluble Aβ assembly: its enhanced formation from Aβ bearing the arctic mutation,” Journal of Biological Chemistry, vol. 282, no. 4, pp. 2646–2655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Robert, O. Dolezal, L. Waddington et al., “Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers,” Protein Engineering, Design and Selection, vol. 22, no. 3, pp. 199–208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Robert, V. A. Streltsov, J. Newman, L. A. Pearce, K. L. Wark, and O. Dolezal, “Germline humanization of a murine Aβ antibody and crystal structure of the humanized recombinant Fab fragment,” Protein Science, vol. 19, no. 2, pp. 299–308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Marín-Argany, G. Rivera-Hernández, J. Martí, and S. Villegas, “An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway,” Biochemical Journal, vol. 437, no. 1, pp. 25–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Morgado, K. Wieligmann, M. Bereza et al., “Moleculat basis of β-amyloid oligomer recognition with a conformational antibody fragment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 31, pp. 12503–12508, 2012. View at Google Scholar
  29. L. A. Miles, G. A. Crespi, L. Doughty, and M. W. Parker, “Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a herical conformation,” Scientific Reports, vol. 3, p. 1302, 2013. View at Publisher · View at Google Scholar
  30. M. P. Lambert, K. L. Viola, B. A. Chromy et al., “Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies,” Journal of Neurochemistry, vol. 79, no. 3, pp. 595–605, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. E. B. Lee, L. Z. Leng, B. Zhang et al., “Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice,” Journal of Biological Chemistry, vol. 281, no. 7, pp. 4292–4299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. M. P. Lambert, P. T. Velasco, L. Chang et al., “Monoclonal antibodies that target pathological assemblies of Aβ,” Journal of Neurochemistry, vol. 100, no. 1, pp. 23–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Lord, A. Gumucio, H. Englund et al., “An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease,” Neurobiology of Disease, vol. 36, no. 3, pp. 425–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Hillen, S. Barghorn, A. Striebinger et al., “Generation and therapeutic efficacy of highly oligomer-specific β-amyloid antibodies,” Journal of Neuroscience, vol. 30, no. 31, pp. 10369–10379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Zhang, J.-S. He, X. Wang et al., “Administration of amyloid-β42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice,” Journal of Alzheimer's Disease, vol. 23, no. 3, pp. 551–561, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Tampellini, J. Magrané, R. H. Takahashi et al., “Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations,” Journal of Biological Chemistry, vol. 282, no. 26, pp. 18895–18906, 2007. View at Publisher · View at Google Scholar · View at Scopus